Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK

Payment Information We Accept Visa, Mastercard, American Express and Discover

 

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Imeglimin Ph3 US and EU Development Discontinued by Metavant; Poxel Seeks Other Options

Here is a brief preview of this blast: Poxel announced that Metavant, its US and EU development partner for Imeglimin, has decided not to move Imeglimin into Ph3 trials. Recall, in Poxel's Q3 '20 earnings update, Poxel disclosed that Metavant was in discussions with FDA regarding the Imeglimin Ph3 program in patients with T2DM and stage 3b or 4 CKD (previous FENIX insight). Below, FENIX provides thoughts on the future of Imeglimin in Western markets.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.